Literature DB >> 20051991

Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression.

Andrzej B Popławski1, Michał Jankowski, Stephen W Erickson, Teresita Díaz de Ståhl, E Christopher Partridge, Chiquito Crasto, Jingyu Guo, John Gibson, Uwe Menzel, Carl Eg Bruder, Aneta Kaczmarczyk, Magdalena Benetkiewicz, Robin Andersson, Johanna Sandgren, Barbara Zegarska, Dariusz Bała, Ewa Srutek, David B Allison, Arkadiusz Piotrowski, Wojciech Zegarski, Jan P Dumanski.   

Abstract

Breast cancer is a major cause of morbidity and mortality in women and its metastatic spread is the principal reason behind the fatal outcome. Metastasis-related research of breast cancer is however underdeveloped when compared with the abundant literature on primary tumors. We applied an unexplored approach comparing at high resolution the genomic profiles of primary tumors and synchronous axillary lymph node metastases from 13 patients with breast cancer. Overall, primary tumors displayed 20% higher number of aberrations than metastases. In all but two patients, we detected in total 157 statistically significant differences between primary lesions and matched metastases. We further observed differences that can be linked to metastatic disease and there was also an overlapping pattern of changes between different patients. Many of the differences described here have been previously linked to poor patient survival, suggesting that this is a viable approach toward finding biomarkers for disease progression and definition of new targets useful for development of anticancer drugs. Frequent genetic differences between primary tumors and metastases in breast cancer also question, at least to some extent, the role of primary tumors as a surrogate subject of study for the systemic disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051991      PMCID: PMC2987320          DOI: 10.1038/ejhg.2009.230

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  44 in total

1.  Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer.

Authors:  T Kuukasjärvi; R Karhu; M Tanner; M Kähkönen; A Schäffer; N Nupponen; S Pennanen; A Kallioniemi; O P Kallioniemi; J Isola
Journal:  Cancer Res       Date:  1997-04-15       Impact factor: 12.701

2.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer.

Authors:  Julian A Schardt; Manfred Meyer; Claudia H Hartmann; Falk Schubert; Oleg Schmidt-Kittler; Christine Fuhrmann; Bernhard Polzer; Marco Petronio; Roland Eils; Christoph A Klein
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

3.  Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis.

Authors:  C Y Shen; J C Yu; Y L Lo; C H Kuo; C T Yue; Y S Jou; C S Huang; J C Lung; C W Wu
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

4.  Evidence for limited molecular genetic heterogeneity as defined by allelotyping and clonal analysis in nine metastatic breast carcinomas.

Authors:  B A Bonsing; P Devilee; A M Cleton-Jansen; N Kuipers-Dijkshoorn; G J Fleuren; C J Cornelisse
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

5.  Gene expression profiles of primary breast tumors maintained in distant metastases.

Authors:  Britta Weigelt; Annuska M Glas; Lodewyk F A Wessels; Anke T Witteveen; Johannes L Peterse; Laura J van't Veer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

6.  A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC-Grb2 interaction.

Authors:  Dujin Zhou; Bin Chen; Jing-Jing Ye; Shiuan Chen
Journal:  Oncogene       Date:  2004-07-08       Impact factor: 9.867

7.  Genetic divergence in the clonal evolution of breast cancer.

Authors:  H Fujii; C Marsh; P Cairns; D Sidransky; E Gabrielson
Journal:  Cancer Res       Date:  1996-04-01       Impact factor: 12.701

8.  Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis.

Authors:  Xishan Hao; Baocun Sun; Limei Hu; Harri Lähdesmäki; Valerie Dunmire; Yumei Feng; Shi-Wu Zhang; Huamin Wang; Chunlei Wu; Hua Wang; Gregory N Fuller; W Fraser Symmans; Ilya Shmulevich; Wei Zhang
Journal:  Cancer       Date:  2004-03-15       Impact factor: 6.860

9.  From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression.

Authors:  Oleg Schmidt-Kittler; Thomas Ragg; Angela Daskalakis; Martin Granzow; Andre Ahr; Thomas J F Blankenstein; Manfred Kaufmann; Joachim Diebold; Hans Arnholdt; Peter Muller; Joachim Bischoff; Detlev Harich; Gunter Schlimok; Gert Riethmuller; Roland Eils; Christoph A Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

10.  Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array.

Authors:  Helena Nord; Christian Hartmann; Robin Andersson; Uwe Menzel; Susan Pfeifer; Arkadiusz Piotrowski; Adam Bogdan; Wojciech Kloc; Johanna Sandgren; Tommie Olofsson; Göran Hesselager; Erik Blomquist; Jan Komorowski; Andreas von Deimling; Carl E G Bruder; Jan P Dumanski; Teresita Díaz de Ståhl
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

View more
  22 in total

1.  P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.

Authors:  André Filipe Vieira; Maria Rita Dionísio; Madalena Gomes; Jorge F Cameselle-Teijeiro; Manuela Lacerda; Isabel Amendoeira; Fernando Schmitt; Joana Paredes
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival.

Authors:  Serena Bonin; Danae Pracella; Renzo Barbazza; Sandro Sulfaro; Giorgio Stanta
Journal:  Virchows Arch       Date:  2015-02-28       Impact factor: 4.064

Review 3.  Evolution of early phase clinical trials in oncology.

Authors:  Nam Q Bui; Shivaani Kummar
Journal:  J Mol Med (Berl)       Date:  2017-11-24       Impact factor: 4.599

4.  Discordant Mutations in Paired Primary and Metastatic Endometrial Adenocarcinomas Identified by Semiconductor-Based Sequencing for Rapid Cancer Genotyping.

Authors:  Colin P Bergstrom; Koen De Geest; Rebecca O'Gara; Christopher L Corless; Terry K Morgan
Journal:  Reprod Sci       Date:  2016-05-11       Impact factor: 3.060

5.  Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes.

Authors:  T H Ho; D J Serie; M Parasramka; J C Cheville; B M Bot; W Tan; L Wang; R W Joseph; T Hilton; B C Leibovich; A S Parker; J E Eckel-Passow
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 6.  Strategies for the discovery and development of therapies for metastatic breast cancer.

Authors:  Bedrich L Eckhardt; Prudence A Francis; Belinda S Parker; Robin L Anderson
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

Review 7.  Bone: A Fertile Soil for Cancer Metastasis.

Authors:  Thomas R Coughlin; Ricardo Romero-Moreno; Devon E Mason; Lukas Nystrom; Joel D Boerckel; Glen Niebur; Laurie E Littlepage
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

8.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

9.  Opportunities and Challenges for Analyzing Cancer Data at the Inter- and Intra-Institutional Levels.

Authors:  Julie Wu; Jordan Bryan; Samuel M Rubinstein; Lucy Wang; Michele Lenoue-Newton; Raed Zuhour; Mia Levy; Christine Micheel; Yaomin Xu; Suresh K Bhavnani; Lester Mackey; Jeremy L Warner
Journal:  JCO Precis Oncol       Date:  2020-06-25

10.  Tumor suppressor PNRC1 blocks rRNA maturation by recruiting the decapping complex to the nucleolus.

Authors:  Marco Gaviraghi; Claudia Vivori; Yerma Pareja Sanchez; Francesca Invernizzi; Angela Cattaneo; Benedetta Maria Santoliquido; Michela Frenquelli; Simona Segalla; Angela Bachi; Claudio Doglioni; Vicent Pelechano; Davide Cittaro; Giovanni Tonon
Journal:  EMBO J       Date:  2018-10-29       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.